Copyright
©The Author(s) 2021.
World J Transplant. Mar 18, 2021; 11(3): 70-86
Published online Mar 18, 2021. doi: 10.5500/wjt.v11.i3.70
Published online Mar 18, 2021. doi: 10.5500/wjt.v11.i3.70
Table 5 Summary of metabolic outcomes in clinical trials
| Parameters | Ferguson et al[33], 2011 (25) | de Graav et al[34], 2017 | Newell et al[35], 2017 (27) | Clinicaltrial.gov 1856257, 2017 (28) | ||||
| Gp1 (Belatacept) | Gp2 (Tacrolimus) | Gp1 (Belatacept) | Gp2 (Tacrolimus) | Gp1 (Belatacept) | Gp2 (Tacrolimus) | Gp1 (Belatacept) | Gp2 (Tacrolimus) | |
| Total CH, Mean (SD) (mg/dL) | NA | NA | 193.34 ± 42.43 | 187.41 ± 42.28 | 187.0 | 156.0 ± 30.4 | 163.7 ± 38.8 | 177.1 ± 25.6 |
| Total TG, Mean (SD) (mg/dL) | NA | NA | 194.86 ± 51.14 | 221 ± 127.87 | 187.0 | 319.3 ± 294.0 | 170.0 ± 118.6 | 125.8 ± 93.0 |
| LDL, Mean (SD) (mg/dL) | NA | NA | 64.78 ± 30.20 | 96.67 ± 55.84 | 114.0 | 69.5 ± 38.0 | 86.3 ± 50.6 | 102.9 ± 17.7 |
| BP mm/Hg (SBP/DBP) (12 mo) | 129.3 ± 19.24/73.3 ± 11.96 | 138.2 ± 19.50/77.6 ± 10.51 | 141.25 ± 14.75/74 .25 ± 8.75 | 142.5 ± 17.31/78.0 ± 13.0 | 146.7 ± 5.1/92.7 ± 9.8 | 147.5 ± 18.7/80.8 ± 12.8 | 133.7 ± 14.7/79.1 ± 10.2 | 135.0 ± 18.9/77.7 ± 10.9 |
- Citation: Kumar J, Reccia I, Virdis F, Podda M, Sharma AK, Halawa A. Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review. World J Transplant 2021; 11(3): 70-86
- URL: https://www.wjgnet.com/2220-3230/full/v11/i3/70.htm
- DOI: https://dx.doi.org/10.5500/wjt.v11.i3.70